Vaxcyte shares are down about 3.4% in Friday trading, a move consistent with a risk-off tape for pre-revenue biotech where supply/dilution dynamics can dominate day-to-day price action. The stock has a fresh dilution “overhang” after a large underwritten equity deal earlier this year and an additional at-the-market (ATM) program that can add shares opportunistically, keeping traders sensitive to any incremental selling pressure. (investing.com)

In late January 2026, Vaxcyte priced an underwritten public offering of 11.0 million shares at $50.00 per share, and the deal later closed with the underwriters’ option fully exercised for total gross proceeds of $632.5 million. Separately, on February 24, 2026 Vaxcyte put in place a new ATM equity sales agreement allowing up to $500 million of common stock to be sold from time to time, which can weigh on sentiment even without a same-day filing or press release. (investing.com)

The most recent major operational update is the March 23, 2026 announcement that Vaxcyte completed enrollment in OPUS-1 (~4,000 participants) and OPUS-2 (~1,300 participants), both Phase 3 studies of its 31-valent pneumococcal conjugate vaccine candidate VAX-31 in adults. The company has guided that OPUS-1 topline data are expected in the fourth quarter of 2026, leaving a long catalyst gap where positioning and financing headlines can influence the stock. (investors.vaxcyte.com)

Near-term, traders will watch for any incremental ATM usage disclosures in periodic filings, additional insider transaction filings, and the company’s next conference appearances or investor materials for changes in timing or trial conduct. Medium-term, focus remains on VAX-31 Phase 3 readouts (OPUS-1 first) and any updates on advancing additional pipeline assets into the clinic during 2026. (stocktitan.net)